Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
881-900 of 936 trials

BI 3009947: Tolerance and Absorption Study

We are testing how different doses of BI 3009947 are tolerated in healthy men. The study also looks at how food and formulations affect how the drug is absorbed into the bloodstream.

Healthy VolunteersSafety phase (I)

HIV Treatment: MK-4646 Study

We are testing a new medication, MK-4646, for people living with HIV. The study aims to see how well it works in managing the virus compared to current treatments.

HIV Infection6-12 monthsSafety phase (I)Infectious Diseases

Cancer Prevention in Lynch Syndrome: Dendritic Cell Therapy

We are testing a new treatment using dendritic cells to help prevent cancer in people with Lynch Syndrome. This study aims to assess its safety and effectiveness in this high-risk group.

Lynch Syndrome>2 yearsSafety phase (I)Internal MedicineOncology

Ovarian Cancer: COM701 Treatment Study

We are testing the safety and effectiveness of COM701 for patients with relapsed platinum-sensitive ovarian cancer. The study aims to see if it can help patients maintain their health without cancer progression.

Ovarian CancerRecurrent Ovarian Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

Immunotherapy for Metastatic Colorectal and Prostate Cancer

We are studying a new treatment using patients' own immune cells to see if it is safe and tolerable for those with advanced colorectal or prostate cancer. The trial will help us understand how well this therapy works in these patients.

Locally Advanced or Metastatic Prostate CancerMetastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteGastroenterologyOncologyUrology

Advanced Solid Tumors: S095035 Treatment Study

We are investigating the safety and effectiveness of S095035, alone and with TNG462, for adults with advanced solid tumors that have a specific genetic deletion. This study aims to find the best dose and assess how well the treatment works.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Gastrointestinal Tumors: OncoGreen Imaging Study

We are testing a new imaging technique using OncoGreen to help surgeons better visualize tumors during surgery. This study is for patients with gastrointestinal tumors who are having surgery to remove their tumors.

Digestive System Tumors>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyInternal MedicineOncology

Advanced Solid Tumors: EP102 Treatment

We are testing the safety and effectiveness of EP102 in patients with advanced solid tumors. This study aims to see if it can provide better treatment options for these patients.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Lactose Intolerance: Gaxilose Oral Treatment

We are testing a new oral treatment called Gaxilose in healthy adults to see if it improves the body's ability to digest lactose. This study aims to understand its potential benefits for those with lactose intolerance.

Lactose Intolerance3-6 monthsSafety phase (I)Gastroenterology

Axial Spondyloarthritis: EAST-1 Trial

We are investigating a new treatment that targets ERAP inhibition for individuals with axial spondyloarthritis. The goal is to see if this approach improves symptoms compared to standard care.

Axial Spondyloarthritis6-12 monthsSafety phase (I)Rheumatology

Parkinson's Disease: New Investigational Compound

We are investigating a new treatment for Parkinson's disease in both healthy individuals and patients. The goal is to assess its safety and effectiveness in managing neurological symptoms.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

Nirogacestat: Understanding Its Effects in Healthy Men

We are studying how the drug Nirogacestat affects liver enzymes in healthy men. This research may help us understand its safety and how it works in the body.

Fibromatosis3-6 monthsSafety phase (I)DermatologyInternal Medicine

Olmsted Syndrome: KM-023 Treatment Study

We are testing a new treatment called KM-023 in healthy volunteers and patients with Olmsted syndrome. The goal is to learn about its safety and how it may help those affected by this condition.

Olmsted Syndrome6-12 monthsSafety phase (I)Dermatology

Long-term Safety Study of GD2IL18CART Treatment

We are following up with patients who received GD2IL18CART to check for any long-term safety concerns and to see how well the treatment is working over time, especially in children.

NeuroblastomaOsteosarcomaEwing's Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Quabodepistat: Understanding Liver Function Impact

We are studying how Quabodepistat is processed in adults with reduced liver function versus those with normal liver function. This research may help improve treatment safety and effectiveness for individuals with liver conditions.

Tuberculosis6-12 monthsSafety phase (I)HepatologyInfectious Diseases

Leriglitazone: Drug Interaction Study

We are studying how the new drug leriglitazone interacts with other medications and food in healthy men. This research may help us understand its safety and effectiveness when taken with certain drugs or after a high-fat meal.

AdrenoleukodystrophySafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNeurology

Migraine Study: Effects of Cilostazol

We are investigating how cilostazol affects migraine headaches in men and women without aura. The study looks at potential differences in response based on sex.

Migraine6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurology

ARGX-121: Safety Study in Healthy Adults

We are assessing the safety of the new treatment ARGX-121 in healthy adult participants. This study aims to ensure the treatment is safe for future use.

Healthy Volunteers6-12 monthsSafety phase (I)AllergologyInfectious Diseases

Advanced-Stage Solid Tumors: JNJ-95437446

We are testing a new treatment for people with advanced-stage solid tumors to see how safe it is and determine the right dosage. This study aims to gather important information for future cancer therapies.

Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Squamous Cell Carcinoma of the Head and Neck (HNSCC)>2 yearsSafety phase (I)Oncology

BP1.15205: New Oral Medication Study

We are testing a new medication called BP1.15205 in healthy volunteers to see how safe it is and how it works in the body. This study will help us understand its effects, including how food might change its absorption.

NarcolepsySafety phase (I)CardiologyNeurology